Stay updated on Combination Therapy in Relapsed Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the Combination Therapy in Relapsed Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combination Therapy in Relapsed Multiple Myeloma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page now presents the ClinicalTrials.gov record for a venetoclax combination-therapy study in relapsed or refractory multiple myeloma, including its study plan, eligibility criteria, outcomes, and locations. It also indicates that the study is active but no longer recruiting.
    Difference
    100%
    Check dated 2026-11-10T06:49:54.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0. The study record page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T02:47:54.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    An NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” terminology across NIH content. The requested study record remains unavailable on the page.
    Difference
    1%
    Check dated 2026-10-27T02:58:11.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-20T05:51:19.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The site footer now identifies the release as v3.7.1 instead of v3.7.0. The study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T08:14:56.000Z thumbnail image
  6. Check
    54 days ago
    Change Detected
    Summary
    The study record now displays a 403 Forbidden error page with updated site chrome including a Home link and a Revision: v3.7.0 note, effectively blocking access to the trial details. Sponsor-related content and links (AbbVie, IPD sharing, SAP, study documents, and related materials) were removed, altering the core context and availability of the trial information.
    Difference
    22%
    Check dated 2026-09-22T05:59:48.000Z thumbnail image

Stay in the know with updates to Combination Therapy in Relapsed Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combination Therapy in Relapsed Multiple Myeloma Clinical Trial page.